However, the use of a CD40 agonist was shown to promote maturation of macrophages and DCs, as well as cross-presentation of tumor antigens to CD8+ T cells, and to facilitate macrophage tumoricidal activity [113]. This evidence concerns the gene CD8A and neoplasm.